Article

Innovation, science take center stage–striving for one goal: A cure!

Scientific advancement and innovation shared the spotlight at the 4th Annual Glaucoma 360 meeting, presented by the Glaucoma Research Foundation (GRF). The meeting brought together leaders in research, industry, ophthalmology, and philanthropy with one goal–to find a cure for glaucoma.

The three-day event, co-chaired by Andrew Iwach, MD, and Adrienne Graves, PhD, centered around the Glaucoma 360 Annual Gala, the New Horizons Forum, and the CME Symposium. Glaucoma 360 was held Feb. 5-7, in San Francisco.

Andrew Iwach, MD, welcomes readers to Ophthalmology Times' coverage of the 2015 Glaucoma 360 meeting.

The Glaucoma 360 Annual Gala featured the presentation of The 2015 Catalyst Award and Visionary Award.

The Catalyst Award was presented to Adrienne Graves, PhD, a global ophthalmic leader who has dedicated her career to advancing innovative concepts so patients could preserve their vision. Dr. Graves has been involved with GRF for many years, serving as a board member and co-developer of Glaucoma 360.

The Visionary Award was shared by Nobel Laureate Shinya Yamanaka, MD, PhD, and Masayo Takahaski, MD, PhD, who was 2014 Stem Cell Person of the Year. Both researchers were honored for their pioneer work to improve global healthcare and treating blinding eye disease.

 

Paul P. Lee, MD, kicked off the New Horizons Forum by delivering the Drs. Henry and Frederick Sutro Memorial Lecture. Dr. Lee addressed the future challenges facing ophthalmologists as well as the opportunities that those challenges will present.

The nucleus of the New Horizons Forum followed with a range of talks on innovation, drugs, devices, and drug delivery. The day-long program also looked at the future of glaucoma research and presented FDA’s new guidance to development.

Dr. Lee returned to the podium to deliver the Shaffer-Hetherington-Hoskins Lecture during the CME Symposium. Dr. Lee’s presentation looked at how science and art combine to improve patient outcomes.

The CME Symposium also featured discussions on the latest clinical advances to treating patients with glaucoma. This special report from Ophthalmology Times, “the official partner and media sponsor” for Glaucoma 360, highlights some of the presentations from the meeting. To experience the meeting to its fullest, readers are encouraged to download the Ophthalmology Times app and interact with the presentations through on-line exclusives, videos, and podcasts.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.